Despite a significant net loss, Allogene Therapeutics Inc (ALLO) advances key trials in large B-cell lymphoma and autoimmune ...

Citizens upgraded Allogene Therapeutics (NASDAQ:ALLO) to Market Perform from Market Underperform on Friday, establishing a $5 ...

The fresh funds will be used to expand clinics, invest in AI-driven healthcare, and enhance patient engagement, strengthening ...

In a report released yesterday, Luca Issi from RBC Capital maintained a Buy rating on Allogene Therapeutics (ALLO – Research Report), with a ...

Piper Sandler analyst Biren Amin maintained a Buy rating on Allogene Therapeutics (ALLO – Research Report) today and set a price target of ...

ALLO's fourth-quarter earnings beat estimates. Devoid of marketed products, the company records no sales in the quarter.

Bengaluru-based Allo Health raises INR 16 Cr in Pre-Series A round led by Zerodha's Rainmatter to expand clinic network and ...

SOUTH SAN FRANCISCO, Calif. (AP) — SOUTH SAN FRANCISCO, Calif. (AP) — Allogene Therapeutics Inc. (ALLO) on Thursday reported a loss of $59.9 million in its fourth quarter. On a per-share basis, the ...

Allo Health raises Rs. 16 crore to expand India’s largest sexual health ecosystem: Our Bureau, Bengaluru Wednesday, March 12, 2025, 17:45 Hrs [IST] Allo Health, India’s leadin ...

Sexual health and wellness startup Allo Health has raised Rs 16 crore in a pre-series A round led by Zerodha's Rainmatter, with participation from existing investors.      The funds will be used to ...